 |
|
Ursolic acid: A promising therapeutic agent for metabolic dysfunction-associated steatotic liver disease via inhibition of SPP1-induced Th17 cell differentiation: Editorial on “Ursolic acid targets secreted phosphoprotein 1 to regulate Th17 cells against metabolic dysfunction-associated steatotic liver disease”
So Jung Kim, Jeongeun Hyun
Clin Mol Hepatol. 2024;30(4):709-713. Published online 2024 Jun 11 DOI: https://doi.org/10.3350/cmh.2024.0412
|
|
Citations to this article as recorded by
 Ursolic acid in colorectal cancer: mechanisms, current status, challenges, and future research directions
Huici Zhang, Xiaoyu Zhang, Xijun Ma, Xuan Wang
Pharmacological Reports.2025; 77(1): 72. CrossRef Therapeutic applications of ursolic acid: a comprehensive review and utilization of predictive tools
Sherien M. Bakry, Riham A. El-Shiekh, Shymaa Hatem, Asmaa A. Mandour, Ahmed M. El-Dessouki, Abeer Bishr, Heba Elosaily, Ahmed F. Mohamed, Shaza M. Elhusseiny
Future Journal of Pharmaceutical Sciences.2025;[Epub] CrossRef The role of SPP1 in MASLD pathogenesis: Therapeutic insights into ursolic acid’s mechanisms of action: Correspondence to editorial on “Ursolic acid targets secreted phosphoprotein 1 to regulate Th17 cells against metabolic dysfunction-associated steatotic
Yiyuan Zheng, Zhekun Xiong, Lina Zhao, Chaoyuan Huang, Qiuhong Yong, Dan Fang, Fengbin Liu, Yong Li
Clinical and Molecular Hepatology.2024; 30(4): 1019. CrossRef
|